Sepsis

12 May, 2025

Procalcitonin-guided early cessation of antibiotics prevents gut inflammation and preserves gut microbiome: Data from the PROGRESS controlled trial

2025-05-12T15:05:05+03:00By hiss|Categories: Biomarkers, Publications|Tags: microbiome, procalcitonin, Sepsis|

Evdoxia Kyriazopoulou, Emmanouil Stylianakis, Georgia Damoraki, Panagiotis Koufargyris, Ioannis Kollias, Konstantina Katrini, Elina Drakou, Konstantinos Marousis, Andronikos Spyrou, Styliani Symbardi, Nikolaos Alexiou, Zoi Alexiou, Malvina Lada, Garyfallia Poulakou, Georgios Chrysos, George Adamis, Evangelos J. Giamarellos-Bourboulis Int J Antimicrob Agents. 2025 Apr 9:107507 DOI: 10.1016/j.ijantimicag.2025.107507 View article 🡆 FundingHellenic Institute for the Study of Sepsis

12 March, 2025

EMBRACE

2025-04-09T09:25:03+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: emapalumab, IFNγ, infections, Sepsis|

Ongoing study Official Study Title EMapalumaB treatment foR Anticipated Clinical benefit in sepsis driven by the Interferon-Gamma Endotype (The EMBRACE trial) Brief Description In a recent analysis of 5,503 patients with sepsis meeting the Sepsis-3 definitions and coming from Germany, Greece and Italy randomized into one discovery set and one validation set, it was

26 February, 2025

Recent advances of precision immunotherapy in sepsis

2025-03-10T10:51:58+03:00By hiss|Categories: Publications|Tags: Anakinra, Interferon-gamma, Sepsis|

Antonios Arapis, Dimitrios Panagiotopoulos, Evangelos J. Giamarellos-Bourboulis Burns & Trauma, 2025, 13, tkaf001 DOI: 10.1093/burnst/tkaf001Download pdf 🡇 Keywords: Precision immunotherapy; Sepsis; Anakinra; Nangibotide; Nivolumab; Interferon-gamma; Growth factors; Adrecizumab

25 October, 2024

Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality

2024-10-25T09:53:56+03:00By hiss|Categories: Biomarkers, Publications|Tags: Interferon-gamma, mortality, Sepsis|

Evangelos J. Giamarellos-Bourboulis, Massimo Antonelli, Frank Bloos, Ioanna Kotsamidi, Christos Psarrakis, Konstantina Dakou, Daniel Thomas-Rüddel, Luca Montini, Josef Briegel, Georgia Damoraki, Panagiotis Koufargyris, Souzana Anisoglou, Eleni Antoniadou, Glykeria Vlachogianni, Christos Tsiantas, Matteo Masullo, Aikaterini Ioakeimidou, Eumorfia Kondili, Maria Ntaganou, Eleni Gkeka, Vassileios Papaioannou, Effie Polyzogopoulou, Armin J Reininger, Gennaro De Pascale, Michael Kiehntopf, Eleni

17 September, 2024

Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19

2024-10-18T11:44:36+03:00By hiss|Categories: Genetics, Publications|Tags: COVID-19, phenotypes, Sepsis|

Eleni Karakike, Simeon Metallidis, Garyfallia Poulakou, Maria Kosmidou, Nikolaos K. Gatselis, Vasileios Petrakis, Nikoletta Rovina, Eleni Gkeka, Styliani Sympardi, Ilias Papanikolaou, Ioannis Koutsodimitropoulos, Vasiliki Tzavara, Georgios Adamis, Konstantinos Tsiakos, Vasilios Koulouras, Eleni Mouloudi, Eleni Antoniadou, Gykeria Vlachogianni, Souzana Anisoglou, Nikolaos Markou, Antonia Koutsoukou, Periklis Panagopoulos, Haralampos Milionis, George N. Dalekos, Miltiades Kyprianou, Evangelos J.

14 March, 2024

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

2024-03-14T14:03:07+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, clinical trial, COVID-19, Sepsis|

Evdoxia Kyriazopoulou, Yehudit Hasin‐Brumshtein, Uros Midic, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Myrto Astriti, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vasiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios

13 February, 2024

REACT

2025-03-13T15:59:08+03:00By hiss|Categories: Ongoing, Sepsis and severe infections, Studies|Tags: CAP, clarithromycin, pneumonia, Sepsis, suPAR|

Ongoing study Official Study Title BiomarkeR-guided EArly Clarithromycin Treatment to prevent sepsis progression in community-acquired pneumonia: The REACT Randomized clinical trial Brief Description The primary objective of the REACT RCT is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of

7 February, 2024

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

2024-02-07T15:45:40+03:00By hiss|Categories: Biomarkers, Publications|Tags: meropenem, qSOFA, Sepsis, suPAR|

Maria Evangelia Adami, Antigone Kotsaki, Nikolaos Antonakos, Efthymia Giannitsioti, Stamatios Chalvatzis, Maria Saridaki, Christina Avgoustou, Karolina Akinosoglou, Konstantina Dakou, Georgia Damoraki, Konstantina Katrini, Panagiotis Koufargyris, Vasileios Lekakis, Antonia Panagaki, Asimina Safarika, Jesper Eugen‐Olsen and Evangelos J. Giamarellos-Bourboulis Critical Care volume 28, Article number: 42 (2024) DOI: 10.1186/s13054-024-04825-2Download pdf 🡇 Funding The

3 August, 2023

Sepsis, a call for inclusion in the work plan of the European Center for Disease Prevention and Control

2023-09-21T14:44:33+03:00By hiss|Categories: Publications|Tags: letter, Sepsis|

Evangelos J. Giamarellos-Bourboulis on behalf of the European Sepsis Alliance (ESA), Annelies S. Zinkernagel on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Edoardo De Robertis on behalf of the European Society of Anesthesiology and Intensive Care (ESAIC), Élie Azoulay on behalf of the European Society for Intensive Care Medicine

15 February, 2023

MODIFY

2024-11-04T11:36:45+03:00By hiss|Categories: Ongoing, Sepsis and severe infections, Studies|Tags: procalcitonin, Sepsis|

Ongoing study Official Study Title A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial) Brief Description The aim of the study is to demonstrate if using a combined strategy of rapid molecular diagnosis with BioFire® FilmArray® Blood Culture Identification 2 Panel and